With over 8700 employees in 40 countries, UCB invests more than 25% of its revenue in cutting-edge research to meet unmet patient needs. The company has a promising pipeline of novel molecules and specializes in neurology and immunology. UCB Ventures, a strategic corporate venture fund, supports early-stage ventures in the pharmaceutical and biotechnology sectors, particularly those focused on neurological diseases and musculoskeletal/bone conditions. The fund has invested in companies like MyHealthTeams and Locana during seed and early Series rounds.